Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 271 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Severe Pneumonia Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT07222384
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 (2025/2026 formulation)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
5 Years to 11 Years
Enrollment
344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
27
States / cities
Palo Alto, California • San Diego, California • Homestead, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 22, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial

NCT04847349
View directory record Official record
Conditions
Covid19
Interventions
OL-1, standard dose, OL-1, high dose, Placebo
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

NCT05567952
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir, placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
67
States / cities
Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 22, 2026, 2:27 AM EDT
Not listed Phase 4 Interventional

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

NCT04429867
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
WellStar Health System
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

NCT04546581
View directory record Official record
Conditions
COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Colorado Springs, Colorado • Lakewood, Colorado • Westminster, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 22, 2026, 2:27 AM EDT
Recruiting Phase 3 Interventional

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

NCT05261139
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 22, 2026, 2:27 AM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 22, 2026, 2:27 AM EDT
Terminated Not applicable Interventional

Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia

NCT04619719
View directory record Official record
Conditions
Covid19
Interventions
Hyperbaric Oxygen Therapy (HBOT)
Device
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Bozeman, Montana • Mineola, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 22, 2026, 2:27 AM EDT
Completed No phase listed Observational

Coagulation Changes Associated With COVID-19 Infection

NCT04460664
View directory record Official record
Conditions
COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

NCT04345614
View directory record Official record
Conditions
Pneumonia
Interventions
Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2), Placebo (Part 2)
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 2:27 AM EDT
Not listed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

NCT04780685
View directory record Official record
Conditions
Covid19
Interventions
hMSC
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fullerton, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir, PF-07321332
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04701658
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05585632
View directory record Official record
Conditions
SARS-CoV-2, Influenza, RSV
Interventions
mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
14
States / cities
DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

NCT04448756
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
M5049, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 22, 2026, 2:27 AM EDT
Completed No phase listed Observational Results available

Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19

NCT04397939
View directory record Official record
Conditions
COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
4,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treat COVID-19 Patients With Regadenoson

NCT04606069
View directory record Official record
Conditions
COVID-19, Lung Inflammation
Interventions
Regadenoson, Placebo Control
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 22, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

NCT04668339
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, Corona Virus Infection
Interventions
ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming, Placebo (two doses), priming, Randomized booster, Placebo booster
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 22, 2026, 2:27 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

NCT05258669
View directory record Official record
Conditions
COVID-19
Interventions
BBV152
Biological
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Tempe, Arizona • Miami, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 22, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

NCT04756141
View directory record Official record
Conditions
Diabetes Mellitus, Covid19
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 22, 2026, 2:27 AM EDT